AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

ConferencerisankizumabupadacitinibPositive

AI Analysis

Summary

AbbVie is presenting 60 abstracts and presentations at the 2026 EADV Congress showcasing clinical and real-world evidence for its dermatology portfolio, including new data for risankizumab and upadacitinib across multiple immune-mediated skin diseases.

Importance:5/10

Sentiment:

0.60

dermatologyclinical datareal-world evidencealopecia areataatopic dermatitishidradenitis suppurativavitiligopsoriasispsoriatic arthritisEADV Congress

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on September 30, 2026 5:00 AM

Read Original